The Proteomics Biomarker Discovery Lab at TTCRC is developing high-throughput proteomics technologies for the rapid identification of biomarker(s) in cancer, that can be easily transferred to diagnostic laboratories, providing a rapid turnaround at a lower cost and decreasing patient waiting time.
Our workflow integrates genomics and transcriptomics with proteomics from tumour samples. The multi-dimensional approach to functional annotation of genomic aberrations offers a more accurate identification of targetable pathways required to deliver precision oncology.
At TTCRC, tumours are characterised at the DNA and RNA level using next generation technology. We will use proteomics to:
- Assess the functional relevance of tumour specific genomic alterations that lead to disease development and progression.
- Identify novel therapeutic targets.
- Investigate the repurposing of conventional drugs to modify or target therapeutically relevant pathways.
The laboratory houses a Triple TOF 6600 Mass Spectrometer from AB Sciex connected online to Ekspert Nano LC 425 system for performing LC-MS based proteomics. The 6600 Mass Spectrometer is capable of detecting mass range of 5 to 40,000 m/z with Q1 mass selection range of 5 to 2250 m/z. This state-of-art mass spec facility has fast acquisition speed (10 ms accumulation time) with no compromise in data resolution (≥ 35000) to identify analytes present in a complex sample. The facility is capable of analysing peptides in micro as well as nanoflow mode.
Supported proteomics workflows by the mass spec at TTCRC are as follows-
- Label-free identification and quantification of proteins using Information dependent acquisition (IDA) MS/MS and Data independent SWATH acquisition (DIA/SWATH).
- Data Dependent Acquisition and Data Independent Acquisition offers relative quantification of thousands of proteins in cell or tissue lysates and hundreds in biofluids such as plasma.
- Label-free quantification of targeted proteins using MRMHR workflow.
Currently we are developing informatics pipelines to analyse the proteomics data, and its integration with corresponding genomics and transcriptomics datasets.
We are always on the lookout for highly motivated candidates with interest and/or experience in Mass spectrometry based proteomics. Do you have hands-on experience with LC-MS? Would you like to join a vibrant group of researchers working to identify better solutions for patients with cancer? If so please do drop us a note via the portal on this website.